$CYDY News

Last published 2w ago

2w agoCYDYCytoDyn Presents Updated Leronlimab Data in Metastatic Colorectal Cancer at ESMO Congress 2026GlobeNewswirePhase 2 CLOVER study enrolled 66 patients across seven sites in metastatic colorectal cancerUpdated data show universal CCR5 expression, early ctDNA reductions and favorable tolerability VANCOUVER, Washington, Oct.
3w agoCYDYCytoDyn Appoints Robert E. Hoffman as Chief Executive OfficerGlobeNewswireDr. Jacob Lalezari to remain with Company in scientific innovation and discovery role VANCOUVER, Washington, Oct. 19, 2026 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB:CYDY) ("CytoDyn" or the "Company"), a
3w agoCYDYCytoDyn to Host Investor WebcastGlobeNewswireVANCOUVER, Wash., Oct. 15, 2026 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB:CYDY) ("CytoDyn" or the "Company"), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized monoclonal
1mo agoCYDYCytoDyn to Present Updated Data from Phase 2 CLOVER Clinical Study at ESMO Congress 2026GlobeNewswireVANCOUVER, Washington, Oct. 08, 2026 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB:CYDY) ("CytoDyn" or the "Company"), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized
1mo agoCYDYCytoDyn Inc. to Present at the Life Sciences Investor Forum on September 17thGlobeNewswireVANCOUVER, Wash., Sept. 15, 2026 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB:CYDY) ("CytoDyn" or the "Company"), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized
2mo agoCYDYCytoDyn Closes $16.5 Million Financing to Fund Continued Development of LeronlimabGlobeNewswireVANCOUVER, Washington, Sept. 01, 2026 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB:CYDY) ("CytoDyn" or the "Company"), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized
5mo agoCYDYCytoDyn Announces First Patient Dosed in Phase 2a Study in Collaboration with Weill Cornell Medicine Evaluating Leronlimab in Alzheimer's DiseaseGlobeNewswirePhase 2a study will evaluate the safety and biological activity of leronlimab in patients over the age of 50 with early-stage, biomarker-confirmed Alzheimer's disease VANCOUVER, Washington, June 11, 2026 (GLOBE
5mo agoCYDY NTRANatera and CytoDyn Announce Strategic Collaboration to Advance ctDNA-Guided Development and Molecular Response Analysis in Metastatic Colorectal CancerBusiness WireNatera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and precision medicine, and CytoDyn Inc. (OTCQB:CYDY) ("CytoDyn"), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized
5mo agoCYDY MRNA OTLC RVMD+1Platform Biotech Models Draw Investor Eyes as Drug-Delivery Markets Head Toward $410 BillionGlobeNewswireAUSTIN, Texas, June 03, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: With oncology drug-development expenses continuing to rise and regulatory approvals becoming harder to secure, biotechnology companies are
6mo agoCYDYCytoDyn to Present at the LD Micro Invitational XVIGlobeNewswireCFO Robert E. Hoffman to deliver company presentation on May 18 at 10 a.m. PT VANCOUVER, Washington, May 15, 2026 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB:CYDY) ("CytoDyn" or the "Company"), a
6mo agoCYDY MRNA NWBO OTLCCNS Drug Delivery Breakthroughs Unlock Significant Biotech Market OpportunitiesGlobeNewswireAUSTIN, Texas, May 11, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: The human brain remains one of the most protected, and difficult to treat, organs in the body. At the center of this challenge is the
6mo agoCYDYCytoDyn Announces First Patient Dosed in Expanded Access Program for Leronlimab in Triple-Negative Breast CancerGlobeNewswireProgram provides access to leronlimab for patients with limited treatment options while supporting ongoing clinical development VANCOUVER, Washington, April 27, 2026 (GLOBE NEWSWIRE) -- CytoDyn Inc.
6mo agoCYDYCytoDyn to Host Investor WebcastGlobeNewswireVANCOUVER, Washington, April 23, 2026 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB:CYDY) ("CytoDyn" or the "Company"), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized
6mo agoCYDYCytoDyn Presents New Leronlimab Data in Metastatic Colorectal Cancer at AACR Annual Meeting 2026GlobeNewswireOngoing Phase 2 study in metastatic colorectal cancer (mCRC) demonstrates early clinical and biomarker activity with leronlimab in combination with TAS-102 and bevacizumab, supporting CCR5 as a therapeutic target
6mo agoCYDYCytoDyn Completes Enrollment in Phase 2 Metastatic Colorectal Cancer StudyGlobeNewswireEnrollment concludes with just over 60 patients participating across seven clinical sites located throughout the United States VANCOUVER, Washington, April 21, 2026 (GLOBE NEWSWIRE) -- CytoDyn Inc.
6mo agoCYDYCytoDyn Presents New Leronlimab Data in Metastatic Triple-Negative Breast Cancer at AACR Annual Meeting 2026GlobeNewswireTranslational study in metastatic triple-negative breast cancer (mTNBC) shows leronlimab-mediated CCR5 inhibition induces PD-L1 expression, modulates immune checkpoint signaling, and is associated with long-term survival
7mo agoCYDYCytoDyn to Present at the AACR Annual Meeting 2026GlobeNewswireVANCOUVER, Wash., April 14, 2026 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB:CYDY) ("CytoDyn" or the "Company"), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized monoclonal
7mo agoCYDYCytoDyn Presents at AACR Special Conference in Cancer Research: Brain CancerGlobeNewswirePreclinical data demonstrates leronlimab-mediated CCR5 inhibition enhances Temozolomide and radiation response in Glioblastoma Leronlimab demonstrates synergy with standard-of-care therapies, supports plan for
8mo agoCYDYCytoDyn Closes $17.5 Million Financing to Fund Continued Development of LeronlimabGlobeNewswireVANCOUVER, Washington, March 05, 2026 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB:CYDY) ("CytoDyn" or the "Company"), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized
8mo agoCYDYCytoDyn Presents Novel CCR5 Inhibition Mechanisms and Long-Term Survival Signals for Leronlimab in Metastatic Breast Cancer at AACR Immuno-Oncology ConferenceGlobeNewswireLeronlimab-mediated CCR5 blockade modulates T-Cell exhaustion pathways and PD-L1 Biology relevant to ICI response Durable Clinical Observations and Favorable Safety Profile Observed in Heavily Pretreated mTNBC Patients
9mo agoCYDYCytoDyn Announces Funding and Initiation of Expanded Access Program for Patients with Triple-negative Breast CancerGlobeNewswireVANCOUVER, Washington, Jan. 27, 2026 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB:CYDY) ("CytoDyn" or the "Company"), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized
11mo agoCYDYCytoDyn to Showcase PD-L1 Upregulation and Improved Survival in Metastatic Triple Negative Breast Cancer at the San Antonio Breast Cancer SymposiumGlobeNewswireLeronlimab treatment is associated with upregulation of PD-L1 in circulating tumor cells and cancer-associated macrophage-like cells Remarkably longer survival was observed in patients treated with leronlimab in
11mo agoCYDYCytoDyn to Present Prolonged Survival Data on Leronlimab in Metastatic Triple-Negative Breast Cancer at the San Antonio Breast Cancer SymposiumGlobeNewswireCompany to deliver a poster presentation on clinical data demonstrating sustained remissionfollowing immune checkpoint inhibitor therapy with or after leronlimab treatmentin patients with metastatic or locally advanced
1y agoCYDYCytoDyn Secures $30 Million Commitment from Yorkville AdvisorsGlobeNewswireVANCOUVER, Washington, Nov. 03, 2025 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB:CYDY) ("CytoDyn" or the "Company"), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized
1y agoCYDYCytoDyn to Present at the LD Micro Main Event XIX Investor ConferenceGlobeNewswireCFO Robert E. Hoffman to deliver company presentation on October 21, 2025 VANCOUVER, Washington, Oct. 09, 2025 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB:CYDY) ("CytoDyn" or the "Company"), a
1y agoCYDYCytoDyn to Present on Leronlimab Induction of PD-L1 and Immune Checkpoint Inhibitor Responses in Metastatic Triple-Negative Breast Cancer at the AACR Special Conference: Mechanisms of Cancer Immunity and Cancer-related AutoimmunityGlobeNewswireCompany to deliver oral and poster presentations for data on leronlimab's action on PD-L1 expression and patient survival in triple-negative breast cancer
1y agoCYDYCytoDyn to Present at the AACR Special Conference: Mechanisms of Cancer Immunity and Cancer-related AutoimmunityGlobeNewswireVANCOUVER, Washington, Sept. 16, 2025 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB:CYDY) ("CytoDyn" or the "Company"), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized
1y agoCYDYCytoDyn Updates Time of Presentation at the H.C. Wainwright 27th Annual Global Investment ConferenceGlobeNewswireVANCOUVER, Washington, Sept. 04, 2025 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB:CYDY) ("CytoDyn" or the "Company"), a clinical-stage biotechnology company advancing leronlimab, a first-in-class humanized
1y agoCYDYCytoDyn to Present at the H.C. Wainwright 27th Annual Global Investment ConferenceGlobeNewswireVANCOUVER, Washington, Aug. 28, 2025 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB:CYDY) ("CytoDyn" or the "Company"), a clinical-stage biotechnology company advancing leronlimab, a first-in-class humanized
1y agoCYDYCytoDyn Announces Encouraging Survival Data in Patients with Metastatic Colorectal Cancer Previously Treated with LeronlimabGlobeNewswirePositive results in patients with advanced mCRC emphasize potential significance of CytoDyn's ongoing Phase II CRC trial Dr. Benjamin Weinberg to present final results at the ESMO Gastrointestinal Cancers Congress
1y agoCYDYCytoDyn Releases ESMO Breast Cancer Meeting PosterGlobeNewswireVANCOUVER, Washington, May 15, 2025 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB:CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for
1y agoCYDYCytoDyn Announces Data Suggesting Novel Mechanism of Action of Leronlimab for the Treatment of Solid TumorsGlobeNewswireSurvival observations in mTNBC patients correlated with increased PD-L1 expression Preliminary evidence suggests leronlimab has potential to turn "cold" tumors "hot" VANCOUVER, Washington, May 13, 2025 (GLOBE
1y agoCYDYCytoDyn Appoints Biotech Veteran Robert E. Hoffman as Chief Financial OfficerGlobeNewswireVANCOUVER, Washington, May 06, 2025 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB:CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for
1y agoCYDYCytoDyn Leadership Team To Attend ESMO Breast Cancer Meeting in Munich, GermanyGlobeNewswireDr. Jacob Lalezari, CEO, and Dr. Richard Pestell, Lead Consultant in Preclinical and Clinical Oncology, to lead CytoDyn group in attendance VANCOUVER, Washington, April 29, 2025 (GLOBE NEWSWIRE) -- CytoDyn Inc.
1y agoCYDYCytoDyn Announces Promising Survival Observations in mTNBC Patients Treated with LeronlimabGlobeNewswireVANCOUVER, Washington, Feb. 24, 2025 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB:CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for
1y agoCYDYCytoDyn Announces Findings of Statistically Significant Fibrosis Reversal Across Studies with SMC LaboratoriesGlobeNewswireVANCOUVER, Washington, Feb. 06, 2025 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB:CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for
1y agoCYDYCytoDyn Appoints Richard Pestell, M.D., Ph.D. as Lead Consultant in OncologyGlobeNewswireVANCOUVER, Washington, Nov. 25, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB:CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for
2y agoCYDYCytoDyn Announces FDA Clearance of Its Phase II Oncology TrialGlobeNewswireVANCOUVER, Washington, Nov. 04, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB:CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for
2y agoCYDYCytoDyn Appoints Dr. Melissa Palmer, M.D., as Lead Consultant in Hepatology; Announces Follow-Up Inflammation Studies with SMC LaboratoriesGlobeNewswireVANCOUVER, Wash., Oct. 30, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB:CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for
2y agoCYDYCytoDyn Appoints Dr. Max Lataillade as Senior Vice President and Head of Clinical DevelopmentGlobeNewswireVANCOUVER, Washington, Oct. 08, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB:CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for
2y agoCYDYCytoDyn Announces Abstract that Highlights Leronlimab's Potential in Mediating ART-Free Viral Control in Infant Rhesus MacaquesGlobeNewswireAbstract to be presented at the 5th annual HIV Research for Prevention Conference Study results highlight potential for treatment VANCOUVER, Washington, Oct. 07, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB:CYDY)
2y agoCYDYCytoDyn Engages Syneos Health as CRO For Its Phase II Oncology TrialGlobeNewswireVANCOUVER, Washington, Oct. 04, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB:CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for
2y agoCYDYCytoDyn Announces Preliminary Findings in Study with SMC LaboratoriesGlobeNewswireVANCOUVER, Washington, Sept. 24, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB:CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for
2y agoCYDYCytoDyn Engages Leading CRO For Phase II Inflammation TrialGlobeNewswireVANCOUVER, Washington, Aug. 23, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB:CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple
2y agoCYDYCytoDyn Announces Completion of FDA Meeting on Phase II Study of Leronlimab in Patients with Relapsed/Refractory Microsatellite Stable Colorectal CancerGlobeNewswireVANCOUVER, Washington, Aug. 12, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB:CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for
2y agoCYDYCytoDyn Announces Settlement with Amarex Clinical Research LLCGlobeNewswireTerms of the settlement include $12,000,000 cash payment to CytoDyn and elimination of $14,000,000 accounts payable liability from the Company's balance sheet VANCOUVER, Washington, July 09, 2024 (GLOBE NEWSWIRE) --
2y agoCYDYCytoDyn Announces Start of Preclinical MASH Study, Results Expected in Fall 2024GlobeNewswireVANCOUVER, Washington, June 27, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB:CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for
2y agoCYDYCytoDyn to Host Webcast to Provide Company UpdateGlobeNewswireVANCOUVER, Washington, May 28, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB:CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for
2y agoCYDYCytoDyn Announces FDA Has Lifted Clinical HoldGlobeNewswireWebcast to Provide Company Update on March 5, 2024 VANCOUVER, Washington, Feb. 29, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB:CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing
2y agoCYDYCytoDyn Announces Submission of Clinical Protocol to FDA and Initiation of Pre-Clinical Study in GlioblastomaGlobeNewswireVANCOUVER, Washington, Feb. 01, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB:CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for